research use only
Cat.No.S5259
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Endogenous Metabolite Inhibitors | Heparan Sulfate 4-HNE (4-Hydroxynonenal) Ademetionine (S-Adenosylmethionine) Sodium L-lactate |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| HL60 cells | Function assay | 80 mM | syrosingopine-metformin-treated HL60 cells grown in medium supplemented with NMN had a partial recovery in ATP levels | 30540938 | ||
| MC3T3-E1 | Cell viability assay | 0.1, 1, 10 mM | 6 h | AlCl3-induced reduction of MC3T3-E1 cell viability was successfully recovered by NMN treatment. | 30292833 | |
| HepG2 | Cell viability assay | 0.5 mM | 48 h | NMN was able to restore reduced NAD concentrations but not cell viability after stimulation with palmitate. | 28974242 | |
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
Water : 67 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 334.22 | Formula | C11H15N2O8P |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1094-61-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | β-NM, NMN | Smiles | C1=CC(=C[N+](=C1)C2C(C(C(O2)COP(=O)(O)[O-])O)O)C(=O)N | ||
| In vitro |
Nicotinamide mononucleotide, the NAD+ precursor, rescues the NAD+/NADH ratio and exerts anti-senescent effects by activating SIRT1. |
|---|---|
| In vivo |
NMN reduces the loss of cochlear hair cells caused by cisplatin and improves hearing in C57BL/6 mice, by supplementation of NAD+ through de novo and salvage synthesis pathways. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06036355 | Not yet recruiting | Postoperative Prevention of Tumor |
Shanghai Cell Therapy Group Co.Ltd |
September 30 2023 | Early Phase 1 |
| NCT05759468 | Recruiting | Type2diabetes|Diabetic Kidney Disease |
Brigham and Women''s Hospital|Boston Medical Center |
April 13 2023 | Phase 2 |
| NCT05789355 | Recruiting | Sickle Cell Disease |
LGD|CEN Biotech|Assistance Publique Hopitaux De Marseille|Etablissement Français du Sang |
April 1 2023 | Not Applicable |
| NCT04910061 | Completed | Healthy Volunteers |
Seneque SA|Dicentra Inc.|LGD |
August 5 2021 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.